StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Arpit Beriwal, Motilal Oswal

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

byArpit Beriwal, Motilal OswalHorizon: NA (inferred Swing (≤2wk))6 Aug 2026via ET Now

Entry₹1,955Inferred
Target₹2,050
Total upside +4.86% (call closed)
Stop lossNot given
At expiry₹1,90420 Aug 2026, 3:30 pm
Expired-2.61%auction close
Follow Arpit Beriwal for new calls(21% target hit, 61 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 236 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 20 Aug 2026
5 supporting2 neutral0 opposing
Supports the BUY call (5)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·19 Aug · today

Sun Pharma and its subsidiaries have won an antitrust litigation in the US related to the Lipitor patent settlement. The US Court of Appeals affirmed a summary judgment in their favor, denying class c

BSE · Company Update·17 Aug · 3d ago

(opens in new tab)

Sun Pharma has received approval to manufacture and market semaglutide in Brazil, indicating a potential market expansion and new product offering.

BSE · Company Update·29 Jul · 3w ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·30 Jul · 3w ago

Sun Pharma announced that Organon shareholders have approved the proposed acquisition, moving forward the company's strategic expansion plans.

BSE · Company Update·24 Jul · 4w ago

(opens in new tab)
Neutral / worth noting (2)

CRISIL has removed the 'Rating Watch with Developing Implications' status and reaffirmed Sun Pharma's long-term bank facilities rating at 'CRISIL AAA/Stable'.

BSE · Company Update·5 Aug · 2w ago

(opens in new tab)

Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27

NSE · Outcome of Board Meeting·31 Jul · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Arpit Beriwal, Motilal Oswal

Every call and its outcome